Premium
Idexx Laboratories Inc (IX1)
TG
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Mr. George J. FennellExec. VP of Global CAG Commercial | -284,00 | 160,97k | Derivative Exercise and Sale | 566,79 | 10,43k | - |
| 2026-06-01 | Mr. George J. FennellExec. VP of Global CAG Commercial | 355,00 | 0,00 | Derivative Exercise and Retained Stock | - | 10,43k | 3,52% |
| 2026-05-07 | Mr. Joseph L. HooleyIndependent Director | 158,00 | 0,00 | Derivative Exercise and Retained Stock | - | 276,00 | 133,90% |
| 2026-05-07 | Mr. Daniel M. JuniusIndependent Director | 257,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,56k | 7,78% |
| 2026-05-07 | Ms. Karen A. PeacockIndependent Director | 101,00 | 0,00 | Derivative Exercise and Retained Stock | - | 102,00 | 10 100,00% |
| 2026-05-07 | Mr. Lawrence D. KingsleyIndependent Lead Director | 339,00 | 0,00 | Derivative Exercise and Retained Stock | - | 8,57k | 4,12% |
| 2026-05-07 | Ms. M. Anne SzostakInitié | 257,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,06k | 14,25% |
| 2026-05-07 | Dr. Sophie V. VandebroekIndependent Director | 257,00 | 0,00 | Derivative Exercise and Retained Stock | - | 8,43k | 3,14% |
| 2026-03-03 | Ms. Sharon E. UnderbergExec. VP, General Counsel, & Corporate Secretary | 197,00 | 99,59k | Derivative Exercise and Retained Stock | 505,53 | 7,14k | 2,84% |
| 2026-03-03 | Dr. Nimrata Khatra HuntAdvisor | -1,76k | 1,12M | Vente | 634,57 | 18,30k | -8,76% |
| 2026-02-27 | Mr. Jonathan J. MazelskyExecutive Chairman | 197,00 | 99,59k | Derivative Exercise and Retained Stock | 505,53 | 83,80k | 0,24% |
| 2026-02-26 | Mr. Jonathan J. MazelskyExecutive Chairman | -23,33k | 12,04M | Derivative Exercise and Sale | 141,60 - 663,04 | 83,80k | - |
| 2026-02-26 | Dr. Nimrata Khatra HuntAdvisor | -2,69k | 1,78M | Vente | 661,54 | 20,06k | -11,84% |
| 2026-02-17 | Dr. Sophie V. VandebroekIndependent Director | -945,00 | 278,53k | Derivative Exercise and Sale | 333,90 - 628,65 | 8,17k | - |
| 2026-02-17 | Dr. Sophie V. VandebroekIndependent Director | -519,00 | 326,22k | Vente | 628,56 | 8,17k | -5,97% |
| 2026-02-19 | Mr. Michael G. EricksonCEO, President & Director | 2,40k | 546,56k | Derivative Exercise and Retained Stock | 141,60 - 544,08 | 14,91k | 19,18% |
| 2026-02-17 | Mr. Michael G. EricksonCEO, President & Director | -5,37k | 2,46M | Derivative Exercise and Sale | 141,60 - 629,86 | 14,91k | - |
| 2026-02-14 | Dr. Nimrata Khatra HuntAdvisor | 1,43k | 0,00 | Derivative Exercise and Retained Stock | - | 22,75k | 6,72% |
| 2026-02-14 | Dr. Nimrata Khatra HuntAdvisor | -1,15k | 726,27k | Derivative Exercise and Sale | 629,35 | 22,75k | - |
| 2026-02-14 | Mr. Michael P. JohnsonExec. VP & Chief HR Officer | 395,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,80k | 16,46% |
| 2026-02-14 | Mr. Michael P. JohnsonExec. VP & Chief HR Officer | -178,00 | 112,02k | Derivative Exercise and Sale | 629,35 | 2,80k | - |
| 2026-02-14 | Mr. Michael J. LaneExec. VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology | 871,00 | 0,00 | Derivative Exercise and Retained Stock | - | 8,25k | 11,81% |
| 2026-02-14 | Mr. Michael J. LaneExec. VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology | -221,00 | 139,09k | Derivative Exercise and Sale | 629,35 | 8,25k | - |
| 2026-02-14 | Mr. Michael SchreckExec. VP & GM of Veterinary Software and Services, Corporate Accounts and Customer Experience | 1,08k | 0,00 | Derivative Exercise and Retained Stock | - | 3,09k | 53,99% |
| 2026-02-14 | Mr. Michael SchreckExec. VP & GM of Veterinary Software and Services, Corporate Accounts and Customer Experience | -876,00 | 551,31k | Derivative Exercise and Sale | 629,35 | 3,09k | - |
| 2026-02-14 | Mr. Jonathan J. MazelskyExecutive Chairman | 1,14k | 0,00 | Derivative Exercise and Retained Stock | - | 83,61k | 1,38% |
| 2026-02-14 | Mr. Jonathan J. MazelskyExecutive Chairman | -915,00 | 575,86k | Derivative Exercise and Sale | 629,35 | 83,61k | - |
| 2026-02-14 | Ms. Sharon E. UnderbergExec. VP, General Counsel, & Corporate Secretary | 581,00 | 0,00 | Derivative Exercise and Retained Stock | - | 6,94k | 9,14% |
| 2026-02-14 | Ms. Sharon E. UnderbergExec. VP, General Counsel, & Corporate Secretary | -251,00 | 157,97k | Derivative Exercise and Sale | 629,35 | 6,94k | - |
| 2026-02-14 | Mr. Martin Alderson SmithInitié | 702,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,16k | 48,25% |
| 2026-02-14 | Mr. Martin Alderson SmithInitié | -302,00 | 190,06k | Derivative Exercise and Sale | 629,35 | 2,16k | - |
| 2026-02-14 | Mr. George J. FennellExec. VP of Global CAG Commercial | 255,00 | 0,00 | Derivative Exercise and Retained Stock | - | 10,08k | 2,60% |
| 2026-02-14 | Mr. George J. FennellExec. VP of Global CAG Commercial | -199,00 | 125,24k | Derivative Exercise and Sale | 629,35 | 10,08k | - |
| 2026-02-14 | Mr. Andrew EmersonExec. VP, CFO & Treasurer | 333,00 | 0,00 | Derivative Exercise and Retained Stock | - | 4,16k | 8,71% |
| 2026-02-14 | Mr. Andrew EmersonExec. VP, CFO & Treasurer | -123,00 | 77,41k | Derivative Exercise and Sale | 629,35 | 4,16k | - |
| 2026-02-09 | Mr. George J. FennellExec. VP of Global CAG Commercial | 1,48k | 100,15k | Derivative Exercise and Retained Stock | 67,85 | 9,82k | 17,68% |
| 2026-02-10 | Mr. George J. FennellExec. VP of Global CAG Commercial | -11,35k | 6,57M | Derivative Exercise and Sale | 67,85 - 650,32 | 9,82k | - |
| 2025-11-07 | Dr. Nimrata Khatra HuntAdvisor | 3,11k | 896,66k | Derivative Exercise and Retained Stock | 288,78 | 21,31k | 17,06% |
| 2025-11-07 | Dr. Nimrata Khatra HuntAdvisor | -9,43k | 2,74M | Derivative Exercise and Sale | 288,78 - 705,54 | 21,31k | - |
| 2025-08-15 | Mr. Jonathan J. MazelskyExecutive Chairman | -1,05k | 0,00 | Other Disposition | - | 82,44k | -1,26% |
| 2025-09-01 | Mr. Martin Alderson SmithInitié | 13,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,43k | 0,91% |
| 2025-09-01 | Mr. Martin Alderson SmithInitié | -5,00 | 3,24k | Derivative Exercise and Sale | 647,09 | 1,43k | - |
| 2025-08-22 | Ms. M. Anne SzostakInitié | -2,19k | 963,82k | Derivative Exercise and Sale | 206,62 - 647,33 | 1,80k | - |
| 2025-08-22 | Ms. M. Anne SzostakInitié | -259,00 | 0,00 | Other Disposition | - | 1,80k | -12,55% |
| 2025-08-12 | Mr. Michael G. EricksonCEO, President & Director | -405,89 | 263,81k | Vente | 649,85 - 649,99 | 11,29k | -3,47% |
| 2025-08-12 | Dr. Nimrata Khatra HuntAdvisor | 1,23k | 299,34k | Derivative Exercise and Retained Stock | 178,26 - 544,08 | 18,19k | 7,23% |
| 2025-08-11 | Dr. Nimrata Khatra HuntAdvisor | -1,20k | 787,84k | Vente | 656,53 | 18,19k | -6,19% |
| 2025-08-12 | Ms. Sharon E. UnderbergExec. VP, General Counsel, & Corporate Secretary | 183,00 | 99,57k | Derivative Exercise and Retained Stock | 544,08 | 6,34k | 2,97% |
| 2025-08-08 | Ms. Sharon E. UnderbergExec. VP, General Counsel, & Corporate Secretary | -5,45k | 2,42M | Derivative Exercise and Sale | 206,94 - 651,60 | 6,34k | - |
| 2025-08-08 | Mr. Jonathan J. MazelskyExecutive Chairman | 183,00 | 109,52k | Derivative Exercise and Retained Stock | 598,49 | 83,49k | 0,22% |
| 2025-08-07 | Mr. Andrew EmersonExec. VP, CFO & Treasurer | 1,45k | 204,90k | Derivative Exercise and Retained Stock | 141,60 | 3,87k | 59,69% |
| 2025-08-07 | Mr. Andrew EmersonExec. VP, CFO & Treasurer | -402,00 | 204,40k | Derivative Exercise and Sale | 141,60 - 650,06 | 3,87k | - |
| 2025-08-06 | Dr. Nimrata Khatra HuntAdvisor | 5,65k | 962,70k | Derivative Exercise and Retained Stock | 141,60 - 178,26 | 18,17k | 45,15% |
| 2025-08-06 | Dr. Nimrata Khatra HuntAdvisor | -7,14k | 3,07M | Derivative Exercise and Sale | 178,26 - 630,91 | 18,17k | - |
| 2025-08-06 | Mr. Jonathan J. MazelskyExecutive Chairman | -29,26k | 16,51M | Derivative Exercise and Sale | 67,85 - 639,37 | 83,31k | - |
| 2025-08-06 | Mr. Michael J. LaneExec. VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology | -8,41k | 2,96M | Derivative Exercise and Sale | 206,94 - 628,89 | 7,72k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
